CALA - Calithera initiates mid-stage lung cancer study with telaglenastat in combination of immunotherapy

Calithera Biosciences (CALA) has commenced Phase 2 (KEAPSAKE) trial of the glutaminase inhibitor telaglenastat (CB-839) in combination with pembrolizumab, carboplatin and pemetrexed.The 120-subject study will evaluate the safety and investigator-assessed progression-free survival of telaglenastat plus this standard-of-care chemoimmunotherapy regimen, as front-line therapy in patients with stage IV non-squamous non-small cell lung cancer, having KEAP1 or NRF2 mutation. Interim data anticipated in 2021.

For further details see:

Calithera initiates mid-stage lung cancer study with telaglenastat in combination of immunotherapy